Nasopharyngeal neoplasm
MONDO:0005375A benign or malignant neoplasm affecting the nasopharynx. Representative examples of benign neoplasms include angiofibroma and squamous papilloma. Representative examples of malignant neoplasms include keratinizing squamous cell carcinoma and nonkeratinizing carcinoma.
Also known as: nasopharyngeal neoplasms, nasopharyngeal tumor, nasopharyngeal tumour, nasopharynx neoplasm, nasopharynx neoplasm (disease), nasopharynx tumor, nasopharynx tumour, neoplasm of nasopharynx
1671 clinical trials for this condition and its sub-types, 37 tagged with Nasopharyngeal neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Nasopharyngeal neoplasm
-
Malignant tumor of nasopharynx 9 trials · 214 incl. sub-types
1 sub-type
- Nasopharyngeal carcinoma 211 trials · 212 incl. sub-types Sub-types →
-
Benign neoplasm of nasopharynx 0 trials
-
Nasopharyngeal teratoma 0 trials
Most studied deeper sub-types
-
Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
Disease control Not yet recruitingThis trial tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) to standard chemotherapy before chemoradiation can improve outcomes for people with advanced nasopharyngeal cancer. About 60 adults with non-metastatic, EBV-positive nasopharyngeal carc…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug cocktail aims to beat back aggressive throat cancer
Disease control Not yet recruitingThis Phase 3 trial tests whether adding a targeted drug (Becotatug Vedotin) to standard immunotherapy and chemo-radiation can improve outcomes for people with high-risk nasopharyngeal cancer. About 514 participants will be randomly assigned to receive either the new combo or stan…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New cocktail of drugs aims to stop High-Risk throat cancer in its tracks
Disease control Not yet recruitingThis Phase 3 trial will test whether adding anlotinib (a drug that cuts off tumor blood supply) to standard immunotherapy and chemotherapy with radiation can improve outcomes for 412 people with high-risk nasopharyngeal cancer. Participants will receive either the new combo or st…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could less immunotherapy be just as good for advanced nose cancer?
Disease control Not yet recruitingThis phase 3 trial will test whether a shorter course of the immunotherapy drug tislelizumab, combined with chemotherapy and radiation, works as well as a longer course for people with advanced nasopharyngeal cancer. About 418 participants will be randomly assigned to receive eit…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New surgical wrap aims to cut palate injuries in half
Symptom relief Not yet recruitingThis study compares two ways to lift the soft palate during throat surgery to see which causes fewer injuries. About 138 people aged 2 to 70 who need this type of surgery will be randomly assigned to either the standard double-strap method or a new full-wrap method. The goal is t…
Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC